Sign In
Buy VYGR
$3.70
-0.0200 (-0.538%)
At Close: Jun 23, 2026
UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches
01:15pm, Friday, 12'th Jun 2026
Voyager Technologies Chairman and CEO Dylan Taylor joins ‘Mornings with Maria' to discuss SpaceX's record-breaking IPO, the rise of the space economy and Voyager's first year as a public company. #f
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
04:01pm, Thursday, 11'th Jun 2026
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced
- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mas
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
07:01pm, Thursday, 07'th May 2026
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.53 per share a year ago.
Voyager Reports First Quarter 2026 Financial and Operating Results
04:01pm, Thursday, 07'th May 2026
- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ende
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -
Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)
01:09am, Tuesday, 14'th Apr 2026
Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two bus
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
03:28am, Monday, 13'th Apr 2026
Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal an
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
02:12am, Monday, 23'rd Mar 2026
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
06:15pm, Monday, 09'th Mar 2026
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
04:01pm, Monday, 09'th Mar 2026
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapie
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
02:22pm, Tuesday, 03'rd Mar 2026
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028
05:05am, Monday, 02'nd Mar 2026
Voyager Therapeutics (NASDAQ: VYGR) outlined what CEO Al Sandrock described as three "pillars of value" for the year ahead during a discussion at Oppenheimer's 36th Annual Life Science Conference, poi
Voyager to Present at Upcoming Investor Conferences
08:00am, Monday, 09'th Feb 2026
LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced
